Novo Nordisk cuts ribbon on $225M U.S. headquarters; Novartis embarks on $60M vaccines expansion in NC;

 @FiercePharma: Novartis forges ahead with expansion at North Carolina vaccines campus, with $60M tech building. Report | Follow @FiercePharma

 @EricPFierce: $65 million DSM cell culture plant in Brisbane part of Australia's $345 million Translational Research Institute. Story | Follow @EricPFierce

> Novo Nordisk ($NVO) opened its new, $225 million U.S. headquarters, designed to cut energy costs by 30% and improve innovation and employee wellness. Report

> Novartis ($NVS) forged ahead with an expansion at its Holly Springs, NC, vaccines campus, with plans for a $60 million technical services building. Report

> U.K. cost-effectiveness watchdogs recommended Bayer's anticoagulant drug Xarelto for new indications in pulmonary embolism and deep vein thrombosis. Report

> Nearly 30% of women fail to pick up their prescriptions for osteoporosis drugs, a Kaiser Permanente study found. Report

> Finland's Orion said first-quarter profits fell on increasing generic competition for its Parkinson's drugs. Report

> Sucampo Pharmaceuticals won the FDA nod for a new indication for its constipation treatment Amitiza. Report

Medical Device News

 @FierceMedDev: CareFusion endures another Class I pump recall. News | Follow @FierceMedDev

 @MarkHFierce: Just attended our FierceBiotech breakfast and covered an R&D panel. Great ideas, but will they boost success rates? | Follow @MarkHFierce

 @DamianFierce: Roche Diagnostics is axing 170 jobs as its dissolves Applied Science biz. News | Follow @DamianFierce

> Cervel Neurotech snags $14.1M for anti-depression device. More

> Patent suit loss tanks Illumina's strong sales quarter. Story

> Report: Electrophysiology device sales grow fastest in Asia. Item

Biotech News

 @FierceBiotech: E&Y: Biotech budget hawks rule the roost in year of mixed performance. Report | Follow @FierceBiotech

 @RyanMFierce: RBC analyst Michael Ye says BMS' PhII data for all-oral reg isn't much of a threat to Gilead. So, again, Gilead is still the frontrunner.  | Follow @RyanMFierce

> Chicago uses its turn in BIO spotlight to promote incubator plans. Story

> GlaxoSmithKline and Avalon Ventures forge $495M biotech startup alliance. News

> Moody's: Deep-pocketed pharma giants poised to boost M&A activity this year. More

Pharma Manufacturing News

> Novartis expanding U.S. vaccine complex. Item

> U.S. lawmakers take another shot at mandating drug tracking system. More

> Fujifilm expands former Merck biologics plant in U.K. News

> DSM sets June launch for Australian biologics plant. Article

Biotech Research News

 @EmilyMFierce: Intel, Oregon Health & Science University partner on genetic profiling project. More | Follow @EmilyMFierce

> Antibody genes linked to ethnicity. Item

> Autistic behavior has genetic basis in mice. Article

> Radioactive bacteria treatment stops metastasis in mice. More

> Columbia researchers identify hundreds of potential metabolic cancer targets. Story

And finally ... Researchers are working on quick-acting treatments for depression. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.